BridgeMD
STEAROID TREATMENT IN PATIENTS WITH HEART ATTACK
EU CTIS ID: 2022-500762-10-00
What this study is testing
To determine whether 250 mg methylprednisolone administrated in the pre-hospital setting reduces final infarct size on cardiac magnetic resonance (CMR) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years including fertile women
- Acute onset of chest pain with < 12 hours duration
- ST-segment elevation myocardial infarction (STEMI) characterized as 2 mm ST elevation in 2 or more V1 through V4 leads, or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation, or 1 mV ST elevation in the limb lead (II, III, and aVF, I, aVL) and V4-V6, or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI)
You likely can't join if
- Presentation with cardiac arrest (out of hospital cardiac arrest (OHCA)
- Time from symptoms onset to primary percutaneous coronary intervention (PCI) > 12 hours
- Known allergy to glucocorticoid or known mental illness with maniac or psychotic episodes
- Previous acute myocardial infarction (AMI) in assumed culprit artery
- Previous coronary artery bypass graft (CABG)
- Unable to read and understand Danish
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.